Tall cell variant of papillary thyroid microcarcinoma: Clinicopathologic features with BRAFV600E mutational analysis

Thyroid

Volumn 23, Issue 12, 2013, Pages 1525-1531

  Bernstein, Jane ^a   Virk, Renu K ^a   Hui, Pei ^a   Prasad, Avinash ^b   Westra, William H ^c   Tallini, Giovanni ^d   Adeniran, Adebowale J ^a   Udelsman, Robert ^a   Sasaki, Clarence T ^a   Roman, Sanziana A ^a   Sosa, Julie A ^a   Prasad, Manju L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; TALL CELL VARIANT PAPILLARY THYROID MICROCARCINOMA; THYROID CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84890327155     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0154     Document Type: Article

References (27)

1. LiVolsi VA, Albores-Saavedra J, Asa SL, Baloch ZW, Sobrinho-Simões M, Wenig B, DeLellis RA, Cady B, Mazzaferri EL, Hay I, Fagin JA, Weber AL, Caruso P, Voutilainen PE, Franssila KO, Williams ED, Schneider AB, Nikiforow Y, Rabes HM, AK Slen L, Ezzat S, Santoro M, Eng C, Harach HR 2004 Papillary carcinoma. In: DeLellis RA, Lloyd RV, LR, Heitz PU, Eng C (eds) Pathology and Genetics: Tumours of Endocrine Organs. World Health Organization Classification of Tumours. IARC Press, Lyon, France, pp 57-66.
2. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
3. Yu XM, Wan Y, Sippel RS, Chen H 2011 Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254: 653-660.
4. Wartofsky L 2012 Management of papillary microcarcinoma: primum non nocere? J Clin Endocrinol Metab 97: 1169-1172.
5. Xing M 2009 BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Ann Surg Oncol 16: 801-803.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
7. Xing M 2005 BRAF mutation in thyroid cancer. Endocrinol Relat Cancer 12: 245-262. (Pubitemid 40896444)
8. Hawk WA, Hazard JB 1976 The many appearances of papillary carcinoma of the thyroid. Clevel Clin Q 43: 207-215.
9. LiVolsi VA 2010 Papillary carcinoma tall cell variant (TCV): a review. Endocrinol Pathol 21: 12-15.
10. Kazaure HS, Roman SA, Sosa JA 2012 Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 19: 1874-1880.
11. Morris LG, Shaha AR, Tuttle RM, Sikora AG, Ganly I 2010 Tall-cell variant of papillary thyroid carcinoma: a matchedpair analysis of survival. Thyroid 20: 153-158.
12. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM 2008 Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113: 48-56. (Pubitemid 351976385)
13. Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE 2009 Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146:1215- 1223.
14. Ghossein RA, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, Tallini G, Shaha A, Singh B, Tuttle RM 2007 Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 17: 655-661. (Pubitemid 47311555)
15. Michels JJ, Jacques M, Henry-Amar M, Bardet S 2007 Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 38: 212-219. (Pubitemid 46096555)
16. Adeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R, Chhieng DC 2011 Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid 21: 717-723.
17. Virk R, Van Dyke A, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML 2013 BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol 26: 62-70.
18. Ostrowski ML, Merino MJ 1996 Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20: 964-974. (Pubitemid 26250636)
19. Terry JH, St John SA, Karkowski FJ, Suarez JR, Yassa NH, Platica CD, Marti JR 1994 Tall cell papillary thyroid cancer: incidence and prognosis. Am J Surg 168: 459-461. (Pubitemid 24345697)
20. Johnson TL, Loyd RV, Thompson NW, Beierwates WH, Sisson JC 1988 Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 12: 22-27. (Pubitemid 18024370)
21. Kakudo K, Bai Y, Liu Z, Li Y, Ito Y, Ozaki T 2012 Classification of thyroid follicular cell tumors: with special reference to borderline lesions. Endocr J 59: 1-12.
22. Akslen LA, LiVolsi VA 2000 Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88: 1902-1908. (Pubitemid 30213001)
23. Ghossein R, LiVolsi VA 2008 Papillary thyroid carcinoma tall cell variant. Thyroid 18: 1179-1181.
24. Choi YJ, Shin JH, Kim JH, Jung SL, Son EJ, Oh YL 2011 Tall cell variant of papillary thyroid carcinoma: sonographic and clinical findings. J Ultrasound Med 30: 853-858.
25. Solomon A, Gupta PK, LiVolsi VA, Baloch ZW 2002 Distinguishing tall cell variant of papillary thyroid carcinoma from usual variant of papillary thyroid carcinoma in cytologic specimens. Diagn Cytopathol 27: 143-148. (Pubitemid 34983199)
26. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66: 6521-6529. (Pubitemid 44085606)
27. Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML 2012 Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 60: 1052-1059.